16-23626343-C-T
Variant summary
Our verdict is Uncertain significance. The variant received 0 ACMG points: 0P and 0B.
The NM_024675.4(PALB2):c.2641G>A(p.Gly881Ser) variant causes a missense change. The variant allele was found at a frequency of 0.0000136 in 1,614,022 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G881D) has been classified as Uncertain significance.
Frequency
Consequence
NM_024675.4 missense
Scores
Clinical Significance
Conservation
Publications
- hereditary breast carcinomaInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen, Ambry Genetics
- Fanconi anemia complementation group NInheritance: AR Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae), ClinGen, Ambry Genetics
- pancreatic cancer, susceptibility to, 3Inheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae)
- familial ovarian cancerInheritance: AD Classification: MODERATE Submitted by: ClinGen
- Fanconi anemiaInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- hereditary nonpolyposis colon cancerInheritance: AD Classification: LIMITED Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Uncertain_significance. The variant received 0 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| PALB2 | NM_024675.4 | c.2641G>A | p.Gly881Ser | missense_variant | Exon 7 of 13 | ENST00000261584.9 | NP_078951.2 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| PALB2 | ENST00000261584.9 | c.2641G>A | p.Gly881Ser | missense_variant | Exon 7 of 13 | 1 | NM_024675.4 | ENSP00000261584.4 |
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152144Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.0000199 AC: 5AN: 251490 AF XY: 0.0000147 show subpopulations
GnomAD4 exome AF: 0.0000123 AC: 18AN: 1461878Hom.: 0 Cov.: 31 AF XY: 0.0000138 AC XY: 10AN XY: 727240 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152144Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74332 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Uncertain:3
The p.G881S variant (also known as c.2641G>A), located in coding exon 7 of the PALB2 gene, results from a G to A substitution at nucleotide position 2641. The glycine at codon 881 is replaced by serine, an amino acid with similar properties. This variant was identified in 1/727 pancreatic cancer probands with positive family history and classified as a variant of uncertain significance by the study authors (Zhen DB et al. Genet. Med., 2015 Jul;17:569-77). This alteration has also been reported in at least one breast cancer patient in a study of 13087 breast cancer cases and 5488 control individuals in the UK (Decker B et al. J Med Genet, 2017 11;54:732-741). This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this alteration remains unclear. -
This missense variant replaces glycine with serine at codon 881 of the PALB2 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has now shown significant association with breast cancer in case-control studies: In one study, this variant was observed in 1/7051 female cases and 2/11241 female controls, as well as in 0/53 male cases and 3/12490 male controls (PMID: 30287823). In a meta-analysis of breast cancer case-control studies, this variant was reported in 4/60462 cases and 3/53458 controls (PMID: 33471991). This variant has been reported in an individual with pancreatic cancer (PMID: 25356972), as well as in 0/1005 cases and 5/23705 controls in a pancreatic cancer case-control study (PMID: 32980694). This variant has been identified in 7/282896 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
- -
Familial cancer of breast Uncertain:2
This sequence change replaces glycine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 881 of the PALB2 protein (p.Gly881Ser). This variant is present in population databases (rs766315705, gnomAD 0.005%). This missense change has been observed in individual(s) with pancreatic and breast cancer (PMID: 25356972, 30287823). ClinVar contains an entry for this variant (Variation ID: 460951). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed for this missense variant. However, the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on PALB2 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
- -
not specified Uncertain:1
Variant summary: PALB2 c.2641G>A (p.Gly881Ser) results in a non-conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2e-05 in 251490 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.2641G>A has been reported in the literature in individuals affected with prostate Cancer and other types of cancer. These reports do not provide unequivocal conclusions about association of the variant with Prostate Cancer. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 28726808, 36898365, 26689913, 30287823, 25356972). ClinVar contains an entry for this variant (Variation ID: 460951). Based on the evidence outlined above, the variant was classified as uncertain significance. -
Pancreatic cancer, susceptibility to, 3 Uncertain:1
Curators: Marc Tischkowitz, Arleen D. Auerbach. Submitters to LOVD: Marc Tischkowitz, Yukihide Momozawa. -
not provided Uncertain:1
In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Identified in individuals with breast, uterine, or familial pancreatic cancer, but also present in unaffected controls (PMID: 25356972, 30287823, 33471991, 26689913); This variant is associated with the following publications: (PMID: 25356972, 28726808, 24485656, 20871615, 19609323, 30287823, 33471991, 32980694, 26689913, 36243179) -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at